In Socket Solutions, LLC, v. Import Global, LLC, No. 2025-1121(Fed. Cir. Aug. 4, 2026), the Federal Circuit vacated the district court's grant of a preliminary injunction barring Import Global from manufacturing, selling, or importing its Neat Socket product, holding that the district court erred in construing the patent claim terms “backplate” and “pin” and in relying on a presumption of irreparable harm.  The decision confirms that the presumption of irreparable harm in patent cases does not survive eBay Inc. v. MercExchange, LLC, 547 U.S. 388 (2006), in the preliminary injunction context.

In Otsuka America Pharmaceutical, Inc. v. Hetero Labs Limited, No. 2025-2016 (Fed. Cir. July 1, 2026), the U.S. Court of Appeals for the Federal Circuit affirmed a preliminary injunction barring Hetero Labs Limited (“Defendants-Appellants”) from launching a generic version of Nuedexta, a drug used to treat neurological disorders.

On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of West Virginia in favor of Regeneron Pharmaceuticals, Inc. against Samsung Bioepis Co., Ltd. (“SB”) and other biosimilar applicants. Regeneron had sued defendants for infringing its U.S. Patent No. 11,084,865, which covers formulations of aflibercept, a fusion protein that binds to vascular endothelial growth factor (VEGF) and is used to treat angiogenic eye diseases. Regeneron markets aflibercept under the brand name EYLEA^®.